Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that a member of the Board of Directors has purchased shares in the company.
The following share purchase has been reported:
|Shares purchased||Total shareholding|
|Peter Høngaard Andersen||Chairman of the Board||2,500||62,065|
Persons under an obligation to report are defined as members of the Board of Directors and members of Executive Management.
For further information regarding Scandion Oncology, please contact:
Bo Rode Hansen, President & CEO
Phone: +45 3810 2017
The information was provided by the contact person above for publication on December 2, 2021, at 17.30 CET.
Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden.
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at email@example.com or +46 (0) 40 200 250.